On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of pharmaceuticals, inviting representatives from the National Medical Products Administration, selected pharmaceutical enterprises, clinical and pharmaceutical experts, media, and Capital Markets research institutions to communicate on recent societal concerns regarding the quality assurance of centralized procurement pharmaceuticals and the innovation and development of the Industry, and to gather opinions and suggestions. At the meeting, heads of companies like Qilu Pharmaceutical, CSPC PHARMA, Sichuan Kelun Pharmaceutical, Zhejiang Jingxin Pharmaceutical, Betta Pharmaceutical, Gan & Lee Pharmaceuticals, and Blue Sail Medical introduced their participation in the procurement of Pharmaceutical consumables and directly addressed public concern, focusing on measures taken by companies to enhance cost control and ensure the quality and supply of selected products. Officials from the Drug Regulation Department of the National Medical Products Administration stated that the regulatory authority promotes the consistency evaluation of quality and efficacy for generic drugs according to the same standard as original research drugs. In the specific work, a complete technical evaluation system aligning with international standards has been established, not only adhering to strict standards during review and approval but also maintaining comprehensive oversight after the product has passed review and been marketed, requiring companies to produce strictly according to the processes applied for consistency evaluation, with any significant changes requiring re-approval. The regulatory authority implements 100% full coverage of production enterprise inspections and random sampling of selected products to ensure "lower prices without compromising quality."